This website uses cookies to provide you with the best possible user experience. We log, strictly anonymously, your user behaviour in order to identify important topics for visitors and to detect any malfunctions that may occur. For more information and to opt out of tracking, please see our Privacy Policy.
OK

Pharmaceutical Industry

Reimbursement for medical products in Germany and internationally is provided according to various frameworks. SKC prepares pharmaceutical companies in a targeted manner so that reimbursement claims can be processed to their fullest extent.

The Challenge

Reimbursement for pharmaceutical innovations
Most markets now make their reimbursement decisions for new innovative active agents as part of a Health Technology Assessment (HTA). In Germany, this corresponds to the early benefit assessment according to AMNOG (Pharmaceuticals Market Reorganization Act). In order to remain competitive, the pharmaceutical industry must be able to detect rapidly changing market conditions early and to adapt to such with the help of innovation.
Companies within the pharmaceutical industry should have answers to the following questions:

  • How can the value of the medical product be best positioned with respect to authorities, hospitals, or other institutions?
  • Which pricing strategy can be implemented in European markets and remain financially viable?
  • How can products contribute to competitive success after their patent protection expires?
  • Which innovations will still lead to sustainable success in ten years?
  • How might the entire business organization be required to adapt to the new challenges?

The solution

Strategy with long-term effect
A strategic approach at all stages of the HTA process is essential for ensuring a successful market entry and exploiting the full growth potential. An excellent strategic execution, its adaptation to changing conditions and the evaluation of markets form a solid basis for this.

Search for alternatives
Pharmaceutical companies must consider alternative reimbursement options, such as NUB, OPS, or DRG applications, or special contract models with payers and insurance companies

Our approach

Experience that creates added value
We use our comprehensive care and industry expertise, our medical know-how, and our experience from a number of projects in providing strategic advice to clients from the pharmaceutical industry. With our excellent and ambitious team, we develop individual strategies and thus support sustainable success. We know the positions of payers precisely from numerous projects. We prepare for reimbursement processes in a targeted manner by applying stress tests to existing arguments early and contrasting them with potential counter-arguments.

  • Market Access

    Development of practical and strategic expertise, such as for the preparation of internationally-focused market entry strategies (incl. AMNOG, NICE, SMC, AIFA, etc.)

  • Interim Management

    Support, as a strategic sparring partner, to the transfer of operative responsibility

  • Value Dossier

    Development of argumentatively convincing value dossiers under consideration of value messages

  • Pricing negotiations

    Simulation, strategic support and handling of pricing negotiations

  • Reimbursement strategies

    Definition and processing of strategic fields of action for an optimal reimbursement

  • Pricing Workshops

    Please find more information of our strategic pricing here.

  • Coaching

    Support of our clients in the development of their business processes

Get in touch

Ihr Ansprechpartner Prof. Matthias P. Schönermark, M.D., Ph.D.
Prof. Matthias P. Schönermark, M.D., Ph.D.
Founder and Managing Director
Fon: +49 511 64 68 14 – 0
Fax: +49 511 64 68 14 – 18
to the top